Rekombinanter EGFR (Nimotuzumab Biosimilar) Antikörper

Produktnummer ABIN7795094

Dieser Humanized Monoklonal Antikörper detektiert spezifisch EGFR (Nimotuzumab Biosimilar) in FACS und in vivo. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter EGFR (Nimotuzumab Biosimilar) Antikörper (ABIN7795094)

Target: EGFR (Nimotuzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser EGFR (Nimotuzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-EGFR (Nimotuzumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Nimotuzumab Biosimilar, EGFR Monoclonal Antibody

Produktmerkmale: Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab. Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain. Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human EGFR / ErbB-1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu EGFR (Nimotuzumab Biosimilar)

Target: EGFR (Nimotuzumab Biosimilar)

Andere Bezeichnung: Nimotuzumab Biosimilar

Substanzklasse: Biosimilar